study: Donor Stem Cell Transplant in High-Risk Hematologic Cancer

[Guest guest]

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic

Cancer

This study is currently recruiting participants.

Verified by National Cancer Institute (NCI), January 2009

RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant

helps stop the growth of cancer cells. It may also stop the patient's immune

system from rejecting the donor's stem cells. The donated stem cells may replace

the patient's immune cells and help destroy any remaining cancer cells

(graft-versus-tumor effect). Sometimes the transplanted cells from a donor can

also make an immune response against the body's normal cells. Giving a

monoclonal antibody, such as alemtuzumab, before transplant and tacrolimus and

methotrexate after transplant may stop this from happening.

http://clinicaltrials.gov/ct2/show/NCT00818961

Contact: R. , MD 404-255-1938 ssolomon@...